IceCure Medical (ICCM) Price to Sales (2021 - 2026)

IceCure Medical (ICCM) has reported Price to Sales for 6 consecutive years, with 13.06 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 87.83% year-over-year to 13.06 in Q2 2026; TTM through Jun 2026 was 3.0, a 85.15% decrease from a year earlier, with the FY2025 full-year figure at 13.2, down 30.19% from the prior year.
• Price to Sales was 13.06 for Q2 2026 at IceCure Medical, down from 24.16 in the prior quarter.
• Over five years, Price to Sales peaked at 107.32 in Q2 2025 and troughed at 13.06 in Q2 2026.
• A 5-year average of 57.77 and a median of 60.53 in 2022 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales soared 220.63% in 2025 and tumbled 87.83% in 2026, its largest moves.
• Over 5 years, Price to Sales stood at 61.1 in 2022, then plunged by 36.19% to 38.99 in 2023, then surged by 82.4% to 71.12 in 2024, then slumped by 50.96% to 34.87 in 2025, then tumbled by 62.55% to 13.06 in 2026.
• The last three Price to Sales figures came in at 13.06 (Q2 2026), 24.16 (Q1 2026), and 34.87 (Q4 2025), per Business Quant data.